Bio-Gene Technology (ASX:BGT) Debt-to-Equity: 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bio-Gene Technology Debt-to-Equity?

Bio-Gene Technology ASX:BGT Debt-to-Equity is 0.00 as of Dec. 2025. The stock has 2 warning signs investors should review. Among 969 Biotechnology companies, Bio-Gene Technology ranks worse than 103199.07% on this metric.

Bio-Gene Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.00 Mil. Bio-Gene Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.00 Mil. Bio-Gene Technology's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$1.17 Mil. Bio-Gene Technology's debt to equity for the quarter that ended in Dec. 2025 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bio-Gene Technology's Debt-to-Equity or its related term are showing as below:

During the past 8 years, the highest Debt-to-Equity Ratio of Bio-Gene Technology was 0.12. The lowest was 0.00. And the median was 0.00.

ASX:BGT's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Bio-Gene Technology  (ASX:BGT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bio-Gene Technology Debt-to-Equity Related Terms

Bio-Gene Technology Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology Debt-to-Equity Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Debt-to-Equity
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.12 0.00 0.00

ASX:BGT vs VRTX, REGN, RVMD: Debt-to-Equity Comparison

For the Biotechnology subindustry, Bio-Gene Technology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Gene Technology Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bio-Gene Technology's Debt-to-Equity falls into.


Bio-Gene Technology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bio-Gene Technology's Debt to Equity Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 1.627
=0.00

Bio-Gene Technology's Debt to Equity Ratio for the quarter that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 1.167
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Bio-Gene Technology (ASX:BGT) has a Debt-to-Equity of 0.00 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bio-Gene Technology and its competitors. According to the industry distribution chart, Bio-Gene Technology ranks #999999 out of 969 companies in the Biotechnology industry.
Is Bio-Gene Technology's Debt-to-Equity too high?
Bio-Gene Technology's current Debt-to-Equity is 0.00. Based on the distribution chart, Bio-Gene Technology ranks #999999 out of 969 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Gene Technology's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Gene Technology ranks #999999 out of 969 companies for Debt-to-Equity. This places Bio-Gene Technology in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 969 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bio-Gene Technology and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Gene Technology's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Debt-to-Equity is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.